Standout Papers

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patien... 2007 2026 2013 2019 523
  1. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 (2007)
    Robert G. Maki, J. Kyle Wathen et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 53 standout
Sub-graph 1 of 22

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
2 intermediate papers

Works of Michael Fanucchi being referenced

Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer
2018
Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer
2006

Author Peers

Author Last Decade Papers Cites
Michael Fanucchi 752 792 328 32 1.4k
Xiaolei Zhu 816 656 591 34 2.0k
Akiko Ono 568 651 292 53 1.5k
F Pein 503 461 662 49 1.7k
Bertrand Billemont 416 635 584 39 1.4k
M. Clerici 1328 1208 490 33 2.1k
E Vélez-García 996 527 455 51 2.2k
Hwee‐Yong Yap 760 395 202 31 1.3k
J J Costanzi 635 281 293 36 1.2k
J H Edmonson 1022 742 329 45 1.8k
Beverly C. Handy 983 426 369 47 1.9k

All Works

Loading papers...

Rankless by CCL
2026